Abstract
Inflammatory neuropathies are treatable immune-mediated disorders of the peripheral nerves, the prevalence of which is higher than previously believed. Although there are now established treatments of proven benefit for acute and chronic inflammatory neuropathies consisting of intravenous immunoglobulins, corticosteroids and plasma exchanges, there are patients who fail to respond to these therapies. Immunosuppressants have been used in these refractory patients and also to lower the requirements of therapies of established efficacy due to their cost (e.g. immunoglobulins) or sideeffects (e.g., corticosteroids). These drugs include “conventional” immunosuppressants like azathioprine, cyclophosphamide etc. and also newer drugs like Rituximab. Other immunomodulatory drugs like interferon beta have also been trialled in some patients. Currently the role of newer drugs like Fingolimod in inflammatory neuropathies is being studied. In this article, the issue of treating inflammatory neuropathies with immunomodulatory and immunosuppressive agents in the context of their potential adverse effects, is reviewed and discussed. The published evidence on these drugs is reviewed, rationale behind the use of such drugs is analyzed and benefit to risk ratio highlighted.
Keywords: Immunomodulation, immunosuppression, inflammatory neuropathy.
Current Drug Safety
Title:Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Volume: 8 Issue: 4
Author(s): Saiju Jacob and Yusuf A. Rajabally
Affiliation:
Keywords: Immunomodulation, immunosuppression, inflammatory neuropathy.
Abstract: Inflammatory neuropathies are treatable immune-mediated disorders of the peripheral nerves, the prevalence of which is higher than previously believed. Although there are now established treatments of proven benefit for acute and chronic inflammatory neuropathies consisting of intravenous immunoglobulins, corticosteroids and plasma exchanges, there are patients who fail to respond to these therapies. Immunosuppressants have been used in these refractory patients and also to lower the requirements of therapies of established efficacy due to their cost (e.g. immunoglobulins) or sideeffects (e.g., corticosteroids). These drugs include “conventional” immunosuppressants like azathioprine, cyclophosphamide etc. and also newer drugs like Rituximab. Other immunomodulatory drugs like interferon beta have also been trialled in some patients. Currently the role of newer drugs like Fingolimod in inflammatory neuropathies is being studied. In this article, the issue of treating inflammatory neuropathies with immunomodulatory and immunosuppressive agents in the context of their potential adverse effects, is reviewed and discussed. The published evidence on these drugs is reviewed, rationale behind the use of such drugs is analyzed and benefit to risk ratio highlighted.
Export Options
About this article
Cite this article as:
Jacob Saiju and Rajabally A. Yusuf, Immunomodulation in Inflammatory Neuropathies: Rationale and Safety, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/15748863113089990040
DOI https://dx.doi.org/10.2174/15748863113089990040 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery The Cellular Effects of Carbon Monoxide in the Airway
Current Molecular Medicine C-Type Lectins on Dendritic Cells and Their Interaction with Pathogen-Derived and Endogenous Glycoconjugates
Current Protein & Peptide Science Early Childhood Caries - A Continuing Oral Health Problem: A Review
Applied Clinical Research, Clinical Trials and Regulatory Affairs Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery The Genetics of Small-Vessel Disease
Current Medicinal Chemistry GapMis: a Tool for Pairwise Sequence Alignment with a Single Gap
Recent Patents on DNA & Gene Sequences Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Mitral Balloon Valvuloplasty: State-of-the-Art Paper
Current Cardiology Reviews Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Strategies for Rot Control of Soybean Sprouts
Recent Patents on Food, Nutrition & Agriculture Disorders of Sex Development: A Review
Current Women`s Health Reviews Physiologic Responses in Anxiety
Current Psychiatry Reviews Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry